Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates
February 15 2023 - 8:00AM
Business Wire
- Lantern is expanding RADR®’s product roadmap to enhance the
development of novel and effective Antibody Drug Conjugates (ADCs)
for the targeted delivery of potent anti-cancer small molecules to
cancer cells.
- RADR®’s AI and ML drug development modules have the potential
to assist in advancing ADC drug candidates from the discovery phase
to first-in-human clinical trials in approximately 2 years or
less.
- Lantern anticipates this expansion will significantly add to
RADR®’s 25+ billion oncology focused data points and library of
over 200+ algorithms.
- The global ADC market is over $4.0 billion and is projected to
reach $14.0 billion by 2027.
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage
biopharmaceutical company using its proprietary RADR® artificial
intelligence ("AI") and machine learning (“ML”) platform to
transform the cost, pace, and timeline of oncology drug discovery
and development, today announced expansions and updates to RADR®’s
product roadmap, which will further enhance its oncology drug
discovery capabilities. These RADR® advancements will focus on
additional innovative AI and ML approaches to develop Antibody Drug
Conjugates (ADCs), which are highly specific cancer-targeted
antibodies linked to potent anti-tumor small molecules and designed
for the treatment of cancer.
“RADR® is an integral component for de-risking and powering the
progression of Lantern’s drug programs, and our recent advances in
moving from program identification through preclinical development
have occurred at speeds rarely seen in oncology drug discovery and
development,” said Panna Sharma, Lantern’s CEO and President.
“Globally, ADC drug programs are one of the fastest growing drug
development markets and are projected to represent a global market
potential of over $14 billion by 2027. The expansion of RADR®’s ADC
capabilities will not only build on its demonstrated ability to
identify synergistic and effective combinations of antibodies and
small molecules, but will also facilitate new high-value
ADC-focused business development opportunities and collaborations,”
continued Sharma.
Highlights of RADR®’s ADC Development Roadmap:
Lantern’s strategic RADR® roadmap for the development of ADCs
was implemented this quarter and will include the following
expansions and updates:
- Development of additional algorithms that can boost prediction
of optimal combinations of ADC components including antibodies,
antibody linkers, payloads, and ADC combinations with other
anticancer small molecules.
- Generation of additional ML-based ADC biomarker signatures that
can predict a cancer's sensitivity to an ADC and guide future
patient selection for clinical trials.
- Use of RADR® guided selection of new molecule payloads with
features of synergy or properties to overcome resistance from
existing ADC payloads.
- Creation of AI modules to predict the immunogenicity of ADC
antibodies to cancer cell surface antigens.
- Expansion of RADR®’s 25+ billion oncology-focused data points
with the addition of immuno-oncology (IO) datasets.
The advancement of RADR®'s product development roadmap will be
accelerated using RADR®'s library of over 200+ advanced algorithms
and automated ML pipelines. This AI strategy will enable the
large-scale analysis of thousands of high-performing model features
through their SHapley Additive exPlanation
(SHAP) scores and can efficiently identify key genes and pathways
that are mechanistically important to drug resistance, quality of
patient outcomes, and improved delivery of ADC drug payloads. These
features can add potential value to ADC programs and prioritize ADC
targets. Additionally, this powerful strategy can be leveraged to
inform downstream ADC design by identifying ADC components that,
when used together, have a high probability of synergy that can
lead to therapeutic response.
Lantern’s RADR® platform excels at automated, large-scale,
biological, and response network analysis, yielding correlations
that can be leveraged in both target identification and drug
response prediction. This biology-driven AI drug development
approach, which leverages over 25 billion oncology focused data
points across thousands of data sets, can be used in augmentation
with existing structural and bond analysis methodologies to further
de-risk ADC drug candidates. This AI-driven approach using RADR® is
expected to deliver an improved understanding of potential clinical
indications and patient stratification approaches for ADC
development.
About Lantern Pharma
Lantern Pharma (NASDAQ: LTRN) is a clinical-stage
oncology-focused biopharmaceutical company leveraging its
proprietary RADR® AI and machine learning platform to discover
biomarker signatures that identify patients most likely to respond
to its pipeline of genomically-targeted therapeutics. By targeting
drugs to patients whose genomic profile identifies them as having
the highest probability of benefiting from the drug, Lantern's
approach represents the potential to deliver best-in-class
outcomes.
Please find more information at: Website: www.lanternpharma.com
LinkedIn: https://www.linkedin.com/company/lanternpharma/ Twitter:
@lanternpharma Lantern’s Monthly Newsletter – SPARK: Sign-up
here
Forward-looking Statements:
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements include, among other
things, statements relating to: future events or our future
financial performance; the potential advantages of our RADR®
platform in identifying drug candidates and patient populations
that are likely to respond to a drug candidate; our strategic plans
to advance the development of our drug candidates and antibody drug
conjugate (ADC) development program; estimates regarding the
development timing for our drug candidates and ADC development
program; expectations and estimates regarding clinical trial timing
and patient enrollment; our research and development efforts of our
internal drug discovery programs and the utilization of our RADR®
platform to streamline the drug development process; our intention
to leverage artificial intelligence, machine learning and genomic
data to streamline and transform the pace, risk and cost of
oncology drug discovery and development and to identify patient
populations that would likely respond to a drug candidate;
estimates regarding patient populations, potential markets and
potential market sizes; sales estimates for our drug candidates and
our plans to discover and develop drug candidates and to maximize
their commercial potential by advancing such drug candidates
ourselves or in collaboration with others. Any statements that are
not statements of historical fact (including, without limitation,
statements that use words such as "anticipate," "believe,"
"contemplate," "could," "estimate," "expect," "intend," "seek,"
"may," "might," "plan," "potential," "predict," "project,"
"target," "model," "objective," "aim," "upcoming," "should,"
"will," "would," or the negative of these words or other similar
expressions) should be considered forward-looking statements. There
are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the impact of the COVID-19
pandemic, (ii) the risk that our research and the research of our
collaborators may not be successful, (iii) the risk that none of
our product candidates has received FDA marketing approval, and we
may not be able to successfully initiate, conduct, or conclude
clinical testing for or obtain marketing approval for our product
candidates, (iv) the risk that no drug product based on our
proprietary RADR® A.I. platform has received FDA marketing approval
or otherwise been incorporated into a commercial product, and (v)
those other factors set forth in the Risk Factors section in our
Annual Report on Form 10-K for the year ended December 31, 2021,
filed with the Securities and Exchange Commission on March 10,
2022. You may access our Annual Report on Form 10-K for the year
ended December 31, 2021 under the investor SEC filings tab of our
website at www.lanternpharma.com or on the SEC's website at
www.sec.gov. Given these risks and uncertainties, we can give no
assurances that our forward-looking statements will prove to be
accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230215005278/en/
Nicole Leber Investor Relations Associate
ir@lanternpharma.com
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jul 2023 to Jul 2024